Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone in early-stage Parkinson's disease
ACTRN12617001578392Phase 2Completed
- Sponsor
- ApoPharma Inc.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of deferiprone in Parkinson's disease (PD), sponsored by ApoPharma Inc. Primary endpoint: Change from baseline to Month 9 in MDS-UPDRS Part III. Started Nov 2016; status: completed.
02
Drugs
deferiprone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12617001578392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001578392.